Last updated: September 8, 2026
Tiagabine hydrochloride is a mature, low-growth antiseizure medicine with limited commercial differentiation. The product was developed as Gabitril by Cephalon and approved by the FDA in 1997 for adjunctive treatment of partial seizures in adults and adolescents. U.S. market value shifted from branded sales to low-priced generic prescriptions after loss of exclusivity and generic entry. Current commercial exposure is concentrated in established epilepsy treatment, with limited potential for expansion because tiagabine is not broadly approved for anxiety, neuropathic pain, or other off-label uses.
The main investment variables are generic price erosion, declining branded relevance, low manufacturing complexity, substitution by newer antiseizure drugs, and the absence of meaningful patent barriers.
What is tiagabine hydrochloride and how is it used?
Tiagabine hydrochloride is the hydrochloride salt of tiagabine, a selective gamma-aminobutyric acid, or GABA, reuptake inhibitor. It increases extracellular GABA by inhibiting the GAT-1 transporter.
The FDA-approved indication is adjunctive therapy for partial seizures in patients aged 12 years and older. It is available as oral tablets in multiple strengths, commonly 2 mg, 4 mg, 12 mg, and 16 mg. The product is administered several times daily during dose titration and maintenance treatment, which makes it less convenient than several newer once- or twice-daily alternatives.
The FDA label warns against use for unapproved indications in patients without epilepsy because seizures and status epilepticus have been reported in that population. This warning materially restricts commercial expansion into psychiatric or pain markets, despite historical off-label investigation. (U.S. Food and Drug Administration [FDA], 2010)
FDA regulatory status
| Regulatory item |
Status |
| Active ingredient |
Tiagabine hydrochloride |
| U.S. brand |
Gabitril |
| Original sponsor |
Cephalon |
| Current large-company ownership context |
Teva acquired Cephalon in 2011 |
| Initial FDA approval |
1997 |
| Dosage form |
Immediate-release oral tablets |
| Approved use |
Adjunctive treatment of partial seizures |
| FDA pathway |
New drug application followed by abbreviated new drug applications for generics |
| Biologic status |
Not applicable |
| Biosimilar exposure |
None |
When did tiagabine lose exclusivity?
Tiagabine’s commercial exclusivity expired years ago. The original product was protected by compound and related patent rights, together with the five-year new chemical entity exclusivity period available under the Hatch-Waxman framework. Generic development began after the relevant exclusivity and patent barriers ceased to prevent approval.
The key commercial event was the transition from Gabitril to generic tiagabine hydrochloride tablets. By the mid-2000s, generic supply had entered the U.S. market, and the product moved into the mature generic phase.
Tiagabine exclusivity timeline
| Period |
Commercial event |
Market effect |
| 1997 |
FDA approves Gabitril |
Cephalon obtains branded market access |
| 1997 to approximately 2002 |
New chemical entity exclusivity period |
ANDA approval is blocked during statutory exclusivity |
| Late 1990s to early 2000s |
Compound and formulation patent coverage |
Delays or constrains generic competition |
| Mid-2000s |
Generic tiagabine approvals and launches |
Price competition begins |
| 2011 |
Teva acquires Cephalon |
Brand assets transfer to Teva |
| 2010s |
Mature generic market |
Brand share and pricing decline |
| 2020s |
Low-growth maintenance market |
Commercial value depends on prescription volume and manufacturing cost |
The precise expiration of individual historical patents should be verified against the FDA Orange Book patent listing and USPTO records for the relevant patent family. Those historical rights no longer create a practical barrier to routine generic entry.
What patents protect tiagabine hydrochloride?
Tiagabine’s original patent estate covered the active compound and pharmaceutical use. Later protection may have covered salt forms, formulations, dosage regimens, or manufacturing processes, but the commercial estate is now largely expired or economically ineffective against approved generic tablets.
Patent categories
Compound patents
The primary compound protection covered tiagabine and related chemical structures. Historical U.S. patent records associated with tiagabine include U.S. patents in the 5-million series assigned to or originating from Novo Nordisk and related development entities.
Method-of-use patents
The commercially relevant method-of-use protection concerned treatment of epilepsy and partial seizures. Because the FDA-approved use is a conventional adjunctive seizure indication, a method patent would have limited value after generic approval if generic labeling remained consistent with the approved indication.
Formulation patents
Immediate-release oral tablets are technically straightforward. Formulation protection is weaker than for controlled-release products, injectable delivery systems, inhaled products, or complex solid dispersions. No widely recognized, commercially dominant extended-release tiagabine product has displaced the immediate-release market.
Manufacturing patents
Manufacturing patents may protect intermediates, stereochemical control, purification, or process economics. They do not appear to create a major market-access barrier because multiple suppliers can manufacture the active ingredient and finished tablets under standard pharmaceutical processes.
How many patents cover tiagabine hydrochloride today?
The historical patent family contains multiple U.S. and foreign filings, but the number of live, commercially blocking patents is effectively zero for ordinary generic tiagabine hydrochloride tablets. Patent-count metrics are less useful than determining whether a listed patent can block ANDA approval or support an injunction.
The current risk profile is therefore different from that of a recently launched branded drug:
- No meaningful composition-of-matter barrier remains for the established product.
- Formulation claims do not appear to create a significant barrier for standard immediate-release tablets.
- Method-of-use claims have limited leverage against a product marketed for the approved epilepsy indication.
- Process claims may affect a particular manufacturer but generally do not prevent alternative manufacturing routes.
What is the Orange Book status of tiagabine?
The Orange Book is relevant for the branded Gabitril NDA and any associated patents or exclusivity entries. The practical market position is generic substitution rather than branded exclusivity.
Approved generic products are typically listed through ANDAs for tiagabine hydrochloride tablets. Orange Book therapeutic-equivalence evaluations determine whether a generic is rated therapeutically equivalent to the reference listed drug. An AB rating, where applicable, supports pharmacy substitution under state law and payer policies.
Orange Book status should be assessed at the product and strength level because listing status, discontinued-product treatment, and patent entries can differ by NDA or dosage strength. No active Orange Book listing is expected to provide a durable commercial barrier comparable to an unexpired composition patent.
Which companies are challenging or supplying tiagabine?
Tiagabine is a genericized market with supply typically distributed among multiple ANDA holders and contract manufacturers. The competitive set has historically included Teva and other large generic manufacturers, including companies operating through U.S. subsidiaries or contract-manufacturing arrangements.
Competition is based on:
- FDA approval and therapeutic equivalence
- Active pharmaceutical ingredient sourcing
- Tablet manufacturing cost
- Wholesaler and group-purchasing access
- Inventory reliability
- Reimbursement participation
- Ability to maintain supply during shortages
The market does not depend on a single innovative sponsor. Teva retains historical brand ownership through Cephalon, but ownership of Gabitril does not create the same economic position as ownership of an exclusivity-protected product.
What patent litigation affects tiagabine?
Tiagabine does not have a major current patent-litigation profile comparable to high-value branded drugs such as oncology products, biologics, or specialty immunology medicines. The main legal activity occurred around the original product’s patent and generic-entry period.
Paragraph IV risk was historically relevant when generic applicants challenged listed patents or asserted noninfringement, invalidity, or unenforceability. Those disputes no longer appear to drive the market because generic entry has already occurred and the product is commercially mature.
No major current settlement structure is known to preserve a meaningful branded monopoly for tiagabine. Generic settlement economics are therefore unlikely to be a major valuation driver.
What is the financial trajectory for tiagabine hydrochloride?
Tiagabine’s financial trajectory follows the standard small-molecule loss-of-exclusivity pattern:
- Branded growth after launch.
- Revenue stabilization during the mature branded period.
- Sharp pricing pressure after generic entry.
- Declining branded revenue and prescription value.
- Long-term generic maintenance supported by recurring epilepsy demand.
Cephalon historically reported Gabitril as part of a broader portfolio. Public company filings did not maintain the product as a major standalone segment in the way companies report flagship assets. After Teva’s acquisition of Cephalon, tiagabine became a small legacy product relative to Teva’s larger generic and specialty portfolios. (Teva Pharmaceutical Industries Ltd., 2011)
Financial profile by phase
| Phase |
Revenue condition |
Margin condition |
Strategic significance |
| Launch and adoption |
Growing branded sales |
High branded gross margin |
Establishes adjunctive epilepsy position |
| Mature brand |
Stable or slowly declining sales |
Strong but exposed to competition |
Supports portfolio cash flow |
| Generic entry |
Rapid price compression |
Margin contraction |
Brand value falls sharply |
| Mature generic |
Low unit pricing with recurring demand |
Manufacturing efficiency determines margin |
Supply reliability becomes central |
| Current market |
Limited nominal growth |
Low to moderate generic margin |
Primarily a maintenance product |
Standalone current revenue estimates are not generally disclosed by Teva. The product is too small within a global pharmaceutical portfolio to provide a transparent public financial series. Market value is better assessed through prescription volume, average selling price, number of suppliers, reimbursement status, and manufacturing cost.
What drives current market demand?
Demand is relatively defensive because epilepsy patients require continuous therapy, but tiagabine is not a first-line growth product.
Demand supports
- Chronic treatment duration
- Established clinical familiarity
- Availability of generic tablets
- Use as adjunctive therapy in partial seizures
- Low acquisition cost
- Inclusion in certain payer formularies
Demand constraints
- Generic price erosion
- Competition from levetiracetam, lamotrigine, lacosamide, oxcarbazepine, topiramate, and other antiseizure medicines
- Multiple-daily dosing considerations
- Narrow FDA indication
- Limited use in new patient starts
- Safety concerns associated with off-label use in patients without epilepsy
- Prescriber preference for newer agents with simpler dosing or broader evidence bases
Tiagabine can retain a role in patients who have failed or cannot tolerate other antiseizure therapies. That creates recurring niche demand but does not support a high-growth commercial trajectory.
How does tiagabine compare with competing antiseizure drugs?
| Drug |
Market position |
Differentiation |
Commercial pressure |
| Tiagabine |
Mature adjunctive option |
GAT-1 inhibition |
High generic substitution and low price |
| Levetiracetam |
Broadly used generic |
Simple dosing and extensive use |
High generic competition |
| Lamotrigine |
Broad epilepsy and bipolar use |
Multiple indications |
Strong generic competition but broader demand |
| Lacosamide |
Established focal-seizure treatment |
Newer mechanism and branded history |
Generic pressure after loss of exclusivity |
| Brivaracetam |
Newer focal-seizure product |
Related to SV2A mechanism |
Higher price and branded differentiation |
| Carbamazepine |
Older broad-use therapy |
Long clinical history |
Low price, tolerability limitations |
| Oxcarbazepine |
Focal-seizure treatment |
Established alternative |
Generic price pressure |
Tiagabine has less commercial breadth than lamotrigine or levetiracetam and less branded differentiation than newer products. Its principal advantage is availability at low cost for selected patients.
What generic launch scenarios exist for tiagabine?
The principal current scenario is continued multi-source generic supply. A new generic entrant could obtain volume by offering lower pricing, improving wholesaler access, or solving supply disruptions. A launch would likely produce incremental share gains rather than create a large new market.
Scenario analysis
| Scenario |
Probability profile |
Commercial outcome |
| Stable multi-source supply |
Base case |
Low price, recurring demand, modest manufacturer margins |
| Supplier exit |
Possible in low-margin markets |
Temporary price increases and shortage risk |
| New low-cost entrant |
Possible |
Additional price erosion and share redistribution |
| Branded relaunch |
Low probability |
Limited uptake unless supported by meaningful differentiation |
| New formulation launch |
Low probability |
Could command a premium only with clinical or adherence benefit |
| Expanded indication |
Low probability |
FDA safety history and limited evidence constrain upside |
What manufacturing and IP barriers remain?
The active ingredient and tablet dosage form do not present major barriers relative to complex pharmaceuticals. The practical barriers are regulatory compliance, validated analytical methods, supply continuity, and commercial scale.
A manufacturer must manage:
- FDA current good manufacturing practice requirements
- API qualification and supply security
- Stability data for each strength
- Bioequivalence requirements
- Controlled inventory and pharmacovigilance
- Low-volume economics
- Pharmacy and wholesaler distribution
The low price of the finished product can make the market unattractive if raw-material costs rise or if a manufacturer operates at subscale. This is a manufacturing-economics risk, not a patent risk.
What is the outlook for tiagabine hydrochloride revenue?
The outlook is stable to declining in nominal value. Prescription demand should remain because epilepsy treatment is chronic, but unit growth is unlikely to offset generic price pressure. Revenue upside would require a differentiated formulation, supply disruption among competitors, or an approved new indication supported by strong clinical evidence.
The most likely commercial profile is:
- Low single-digit or negative revenue growth
- Persistent generic substitution
- Limited branded contribution
- Modest value to manufacturers with efficient production
- Low probability of material investor-relevant revenue expansion
- Greater relevance as a portfolio maintenance product than as a growth asset
Key Takeaways
- Tiagabine hydrochloride is a mature generic antiseizure medicine.
- Gabitril was FDA-approved in 1997 for adjunctive treatment of partial seizures.
- U.S. market exclusivity ended years ago, and generic entry removed the principal commercial barrier.
- The current market has little meaningful patent protection for standard immediate-release tablets.
- Teva inherited the brand through its acquisition of Cephalon, but tiagabine is not a major separately reported revenue asset.
- Generic competition, low pricing, and newer antiseizure drugs limit growth.
- Demand is supported by chronic epilepsy treatment and low acquisition cost.
- The principal risk is supplier withdrawal or manufacturing disruption, not patent litigation.
- Revenue is likely to remain stable to declining, with limited upside absent a differentiated formulation or new approved indication.
FAQs
Is tiagabine hydrochloride still commercially available?
Yes. Tiagabine hydrochloride remains available as a generic oral tablet and may also be marketed under the Gabitril brand, subject to supplier and regional availability.
Is tiagabine hydrochloride a controlled substance?
No. Tiagabine is not federally scheduled as a controlled substance in the United States.
Can generic tiagabine replace Gabitril?
An FDA-approved therapeutically equivalent generic can generally be substituted for Gabitril under applicable state pharmacy-substitution rules and payer policies.
Does tiagabine have biosimilar competition?
No. Tiagabine is a chemically synthesized small molecule, not a biologic. Its competitive products are generics approved through the ANDA pathway, not biosimilars.
Could a new tiagabine formulation create substantial market value?
A new formulation could create limited value if it improves dosing convenience, adherence, tolerability, or pharmacokinetics. The opportunity would be constrained by the small indication, generic pricing, existing competition, and the need for FDA approval and differentiated clinical evidence.
References
-
U.S. Food and Drug Administration. (2010). Gabitril (tiagabine hydrochloride) tablets: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA, Center for Drug Evaluation and Research.
-
Teva Pharmaceutical Industries Ltd. (2011). Annual report 2011. Teva Pharmaceutical Industries Ltd.
-
U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.
-
National Library of Medicine. (n.d.). Tiagabine hydrochloride. DailyMed.
